Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.
about
Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the HeadCritical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpoxNonreplicating influenza A virus vaccines confer broad protection against lethal challengeMVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 virusesAn evaluation of the emerging vaccines against influenza in children.IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protectionModified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.Influenza vaccines: a moving interdisciplinary field.MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization.Several hemagglutinins of same serotype for induction of broad immunity against influenza A virus antigenic drift variants: WO2008048984.Targets for the induction of protective immunity against influenza a viruses.Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccinesNew technologies for influenza vaccines.Novel viral vectored vaccines for the prevention of influenza.Vaccine development for protecting swine against influenza virus.Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in miceA single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model.Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAsPercutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored VaccinesProduction of prostaglandin E₂ in response to infection with modified vaccinia Ankara virusSwine influenza vaccines: current status and future perspectives.Pre-existing immunity against vaccine vectors--friend or foe?Controlling influenza by cytotoxic T-cells: calling for help from destroyers.Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass.Concomitant type I IFN receptor-triggering of T cells and of DC is required to promote maximal modified vaccinia virus Ankara-induced T-cell expansion.
P2860
Q26783897-9DAF0168-0C26-46C6-A859-ECD2A0D888B0Q27346933-C766AADA-AC13-4554-B163-D6888A2A1E31Q28392109-6EB2F154-3821-4493-8BA7-017886C0A0A1Q30358935-CF113100-AFB3-4EC3-A9C3-04518DC653B8Q30359375-E4CA5978-E173-4BD7-AA4B-1EE0F7E6AD30Q30361079-3E45596E-F280-45B4-90E9-5E4294598050Q30366666-8198A598-D64B-4CBD-9156-8951C2457259Q30367695-2AB16109-5736-40A9-80E2-1C9BCD321068Q30382567-CC297AB8-C221-4246-884E-B2B6027BEF53Q30385956-26C8F673-16F2-4937-8A4D-31E1FE7A7243Q30408100-1E46D4BE-E0B0-435D-B0D0-C0577141F0C6Q30408295-C98B3AE6-F259-454D-8679-426F3967023CQ30411859-55790B04-9CCD-4067-BDB4-18506B570E27Q30418570-3E93477A-0601-4C18-BCF6-29FF8D9D03B2Q30424943-43F0F816-D2B5-4AEF-866F-0B4D19086618Q30425194-BA3FBA03-9184-4130-9541-4B38AEDE1F6CQ35474243-1CD4C172-FF72-4A17-B231-4D11D4B5262DQ35634159-32671B98-6CF8-49C0-9480-A45E7135AADBQ35928588-30FF7A55-7154-40B8-A4A8-B6D59F67D9AFQ35962511-666DE58A-062D-4ECC-9ABA-06A1BF206B65Q37749889-D6626A89-3784-4914-A965-91C44E1E6D4EQ38061876-87F9C292-1CDF-4335-AD4A-77BFA3D07381Q40730765-6508E515-CBC0-4C02-B081-2758A872DAC3Q43108138-B7F25D44-0CE1-4D6C-96A2-808CA745DB07Q45373249-ED0DC993-63EA-4EE5-9736-76FB14B82994
P2860
Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.
@ast
Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.
@en
type
label
Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.
@ast
Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.
@en
prefLabel
Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.
@ast
Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.
@en
P2860
P356
P1476
Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.
@en
P2093
Gerd Sutter
P2860
P304
P356
10.1586/ERV.09.4
P577
2009-04-01T00:00:00Z